Landmark Petition to Reschedule Psilocybin filed with DEA
February 4, 2022 (Investorideas.com Newswire) Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on the effectiveness of psilocybin in mental health care
Following issuance of the Ninth Circuit's opinion in AIMS v DEA on Monday (1/31), finding lack of jurisdiction to review the DEA's refusal to allow access to psilocybin pursuant to duly enacted Right to Try laws, Petitioners have filed a Petition for Rescheduling of Psilocybin from schedule I to schedule II. The Petition offers DEA a way to create a pathway so that terminally ill patients can access to psilocybin.
In a letter to the DEA sent on January 18, bipartisan Congressional members encouraged DEA to use its power to create a pathway to access psilocybin, shown to be remarkably effective in relieving anxiety and depression in patients with advanced illness. Given that the interests of terminally ill patients are at stake, where the advance of illness makes time short, there is an urgency for DEA's action on the Petition. Congressional interest in the DEA's response to this Petition will likely be keen.
On today's Psychoactive Podcast Matt Johnson, the first researcher to be appointed to an endowed chair in psychedelic studies, the Susan Hill Ward Professor in Psychedelics and Consciousness at Johns Hopkins University, says leaving psilocybin on schedule I is "absolutely absurd."
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Sign up for free stock news alerts at Investorideas.com